论文部分内容阅读
新的药物治疗间歇性跛行尚未成功;在改善雷诺氏征象的症状方面有新进展;近年来预防性治疗血栓性静脉炎方面则有较大进展。间歇性跛行:布酚宁兴奋β受体使肌肉的血流量增加;妥拉林阻断α受体增加皮肤的血流量。直接舒张血管的药如异舒普林等既增加皮肤血流重也增加肌肉血流量。研究表明上述三类药对正常人收缩的血管确有一定舒张作用,可增加小腿和肌肉血流重。但对间歇性跛行病人疗效不明显。己酮可可碱治疗间歇性跛行的新药,可经减少血液粘度来增加血流量。82例病人口
New drug treatment of intermittent claudication has not been successful; new progress has been made in improving the symptoms of Raynaud’s signs; and in recent years, there has been much progress in the preventive treatment of thrombophlebitis. Intermittent claudication: Clopidoflurane excites the beta receptors to increase the muscle blood flow; Torahin blocks the alpha receptors and increases the skin’s blood flow. Diastolic blood vessels such as isoprenaline directly increase blood flow to the skin also increases muscle blood flow. Studies have shown that the three types of drugs on the contraction of normal blood vessels do have a certain degree of relaxation, can increase the calf and muscle blood flow weight. But the effect of intermittent claudication patients is not obvious. Pentoxifylline, a new drug for the treatment of intermittent claudication, increases blood flow by reducing blood viscosity. 82 cases of patients mouth